Kemp Dolliver
Stock Analyst at Brookline Capital
(0.46)
# 4,069
Out of 4,959 analysts
18
Total ratings
30.77%
Success rate
-18.47%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNTX Rein Therapeutics | Downgrades: Hold | n/a | $1.15 | - | 1 | Aug 19, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $5.65 | +218.58% | 1 | Jul 21, 2025 | |
| LSTA Lisata Therapeutics | Maintains: Buy | $20 → $32 | $2.47 | +1,195.55% | 1 | Jul 15, 2025 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $17 | $8.54 | +99.18% | 1 | Dec 5, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $5.70 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $0.78 | +363.74% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.10 | +1,614.29% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $2.41 | +1,202.90% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $8.00 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $59.16 | +69.03% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $57 | $2.40 | +2,271.84% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $25 | $3.44 | +626.74% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $5.12 | +266.21% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.81 | +882.44% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.88 | +545.27% | 1 | Feb 2, 2022 |
Rein Therapeutics
Aug 19, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.15
Upside: -
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $5.65
Upside: +218.58%
Lisata Therapeutics
Jul 15, 2025
Maintains: Buy
Price Target: $20 → $32
Current: $2.47
Upside: +1,195.55%
Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $8.54
Upside: +99.18%
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $5.70
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $0.78
Upside: +363.74%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.10
Upside: +1,614.29%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $2.41
Upside: +1,202.90%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $8.00
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $59.16
Upside: +69.03%
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.40
Upside: +2,271.84%
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $3.44
Upside: +626.74%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $5.12
Upside: +266.21%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.81
Upside: +882.44%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.88
Upside: +545.27%